A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer

被引:13
作者
Chu, Franklin M. [1 ]
Sartor, Oliver [2 ,3 ]
Gomella, Leonard [4 ]
Rudo, Todd [5 ]
Somerville, Matthew C. [6 ]
Hereghty, Belinda [6 ]
Manyak, Michael J. [6 ]
机构
[1] San Bernardino Urol Associates, San Bernardino, CA 92404 USA
[2] Tulane Sch Med, Dept Med, New Orleans, LA USA
[3] Tulane Sch Med, Dept Urol, New Orleans, LA USA
[4] Thomas Jefferson Univ, Dept Urol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[5] GlaxoSmithKline, Collegeville, PA 19426 USA
[6] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA
关键词
Castration-resistant prostate cancer (CRPC); Dutasteride; Bicalutamide; Prostate-specific antigen (PSA); Androgen deprivation therapy (ADT); ANDROGEN DEPRIVATION THERAPY; PHASE-II; INHIBITOR; RECURRENT; SURVIVAL; TESTOSTERONE; CHEMOTHERAPY; RADIOTHERAPY; COMBINATION; MANAGEMENT;
D O I
10.1016/j.ejca.2015.04.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Bicalutamide blocks androgen action and is frequently used in men with non-metastatic, castration-resistant prostate cancer (CRPC). By reducing intracellular dihydrotestosterone, dutasteride (dual 5-alpha reductase inhibitor) could increase the effectiveness of bicalutamide in this setting. The objective of the study is therefore to prospectively evaluate dutasteride plus bicalutamide in men with asymptomatic, non-metastatic CRPC with rising prostate-specific antigen (PSA). Methods: Prostate cancer patients with rising PSA whilst on first-line androgen deprivation therapy (ADT) were randomised (1:1) in a double-blind trial to receive bicalutamide 50 mg plus placebo or bicalutamide 50 mg plus dutasteride 3.5 mg once daily for 18 months. Randomisation was stratified by centre; treatment assignments were generated using GlaxoSmithKline's RandAll System. Subjects who completed 18 months could participate in the 2-year extension. Central laboratory and study sites/monitors remained treatment-blinded. Primary end-point was time to disease progression (TDP) up to 42 months (defined as PSA progression from baseline or nadir, radiographic disease progression, death from prostate cancer or receipt of rescue medication). Findings: There was no statistically significant difference in TDP in 127 men treated with bicalutamide/dutasteride (n = 62) compared with bicalutamide/placebo (n = 65) (hazard ratio (HR) = 0.94 [95% confidence interval (CI) 0.61, 1.46]; p = 0.79). The estimated median TDP was 425 days (95% CI 302, 858) in the bicalutamide/placebo group and 623 days (95% CI 369, 730) in the bicalutamide/dutasteride group. There was no statistically significant difference between the treatment groups for any secondary efficacy end-points, including time to treatment failure or PSA response. In the multivariate analysis, age, non-White race, higher baseline testosterone and lower baseline PSA were associated with longer TDP. Adverse events were comparable between treatment groups. Interpretation: In men with non-metastatic CRPC, adding dutasteride to bicalutamide did not significantly prolong TDP. Prospective data are provided concerning the common practice of using bicalutamide in this setting. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1555 / 1569
页数:15
相关论文
共 33 条
[1]   Effect of Dutasteride on the Risk of Prostate Cancer. [J].
Andriole, Gerald L. ;
Bostwick, David G. ;
Brawley, Otis W. ;
Gomella, Leonard G. ;
Marberger, Michael ;
Montorsi, Francesco ;
Pettaway, Curtis A. ;
Tammela, Teuvo L. ;
Teloken, Claudio ;
Tindall, Donald J. ;
Somerville, Matthew C. ;
Wilson, Timothy H. ;
Fowler, Ivy L. ;
Rittmaster, Roger S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13) :1192-1202
[2]   The backdoor pathway to dihydrotestosterone [J].
Auchus, RJ .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (09) :432-438
[4]   A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy na⟨ve castration-resistant prostate cancer [J].
Azad, Arun A. ;
Beardsley, Emma K. ;
Hotte, Sebastian J. ;
Ellard, Susan L. ;
Klotz, Lawrence ;
Chin, Joseph ;
Kollmannsberger, Christian ;
Mukherjee, Som D. ;
Chi, Kim N. .
INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) :746-752
[5]   The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases [J].
Azzouni, Faris ;
Godoy, Alejandro ;
Li, Yun ;
Mohler, James .
ADVANCES IN UROLOGY, 2012, 2012
[6]   A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer [J].
Beardsley, Emma K. ;
Hotte, Sebastien J. ;
North, Scott ;
Ellard, Susan L. ;
Winquist, Eric ;
Kollmannsberger, Christian ;
Mukherjee, Som D. ;
Chi, Kim N. .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) :1652-1659
[7]  
Bramson HN, 1997, J PHARMACOL EXP THER, V282, P1496
[8]   Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial [J].
Denham, James W. ;
Joseph, David ;
Lamb, David S. ;
Spry, Nigel A. ;
Duchesne, Gillian ;
Matthews, John ;
Atkinson, Chris ;
Tai, Keen-Hun ;
Christie, David ;
Kenny, Lizbeth ;
Turner, Sandra ;
Gogna, Nirdosh Kumar ;
Diamond, Terry ;
Delahunt, Brett ;
Oldmeadow, Christopher ;
Attia, John ;
Steigler, Allison .
LANCET ONCOLOGY, 2014, 15 (10) :1076-1089
[9]   Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial [J].
Fleshner, Neil E. ;
Lucia, M. Scott ;
Egerdie, Blair ;
Aaron, Lorne ;
Eure, Gregg ;
Nandy, Indrani ;
Black, Libby ;
Rittmaster, Roger S. .
LANCET, 2012, 379 (9821) :1103-1111
[10]   Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy [J].
Fujii, Yasuhisa ;
Kawakami, Satoru ;
Masuda, Hitoshi ;
Kobayashi, Tsuyoshi ;
Hyochi, Nobuhiko ;
Kageyama, Yukio ;
Kihara, Kazunori .
BJU INTERNATIONAL, 2006, 97 (06) :1184-1189